
    
      The study was closed to enrollment on 14 Jan 2011 and terminated secondary to excessive
      screen failure rate and for business reasons associated with Pfizer's business decision to
      stop development of the figitumumab compound. Safety concerns did not contribute to the
      decision to terminate this clinical trial.
    
  